• Shattuck Labs stock is among today’s weakest performers. What’s weighing on STTK shares?The company announced data from its Phase 1 clinical trial, which demonstrated encouraging results for inflammatory bowel disease, contributing to the stock’s upward momentum as the broader market sees gains, with S&P 500 futures up 0.7%.Shattuck Labs is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases.STTK Stock Jumps On SL-325 Phase 1 Trial ResultsShattuck Labs has revealed positive data from its Phase 1 clinical trial of SL-325, a potential first-in-class antibody targeting the DR3 receptor, which could improve treatment outcomes for patients with inflammatory bowel disease.The trial results indicate a favorable safety profile and effective receptor occupancy, setting the stage for further development in a Phase 2b trial expected to begin in the third quarter of 2026.STTK Technical Analysis: Key Support, Resistance and RSIThe stock’s current price of $4.86 is significantly below its 20-day simple moving average (SMA) of $5.95, indicating potential resistance at that level.The Relative Strength Index (RSI) is currently at 24.11, suggesting that the stock is in oversold territory, which may indicate a reversal or a bounce-back opportunity in the near term.